Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Pharma & MedTech Business Intelligence’s The Pink Sheet Daily, in “US FDA’s New Game Plan for Digital Health,” by Ferdous Al-Faruque. (Read the full version – subscription required.)

Following is an excerpt:

At least one industry representative said the announcement from Gottlieb was a highly positive development for health software developers. “Holy smokes. It’s amazing what an election will do;” said Bradley Thompson, counsel for the Clinical Decision Support (CDS) Coalition, an industry group of health-care software developers. “All in all, I feel like I’ve died and gone to heaven:” …

Thompson, with the CDS Coalition and also an attorney with Epstein Becker & Green, strongly supports the concept, and says it is one his group has advocated for. “In advocating for the pre-check idea, we have advanced the notion that software creates certain unique opportunities to collect data on an almost rea l-time basis from the marketplace, and make continuous improvement through changes to the software;” he said. “We’ve argued that that strength of the software development model could be used as a basis for creating the expedited pathway to market. It would seem as though FDA is interested in pursuing that line of thought:’ …

Thompson says that since 2011, the CDS Coalition has been urging FDA to publish guidance to clarify the scope of its oversight of clinical decision support software and tackle other unresolved digital health issues. While even just a few months ago, the agency seemed unsure what to do in the area, the attorney noted, Gottlieb now appears to be accelerating forward. “That is music to my ears;” Thompson said. “Indeed, it seems that FDA is committed to going beyond just the technology addressed in the 21st Century Cures Act;” he said. “Legislation always covers at best a few of the larger categories, and there is truly much more work to be done. Although it is not specifically addressed, we are very hopeful that the plan includes addressing software used in connection with pharmaceuticals:”

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.